BRIEF

on Bb Biotech (isin : CH0038389992)

BB Biotech AG Reports Profit in 2024 Fiscal Year

BB Biotech AG has announced a profit of approximately CHF 76 million for the 2024 fiscal year, a significant recovery from the CHF 207 million loss in the previous year. These preliminary unaudited figures showcase the positive performance of the companies within its investment portfolio. The resurgence in profit highlights the impact of favorable share price developments of these firms.

BB Biotech AG, a major investor in innovative drug developers primarily located in the US and Western Europe, will publish all relevant portfolio data on January 24, 2025. The complete annual report will be available on February 21, 2025. This information is crucial for investors and stakeholders to assess the company's financial health and strategic direction.

R. E.

Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all Bb Biotech news